Table 2.
CSF-corrected metabolite concentrations
| PBO | AMP | MA | ||||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | |
| Primary measures | ||||||
| Glx | 12.92 | 1.44 | 13.91***a | 1.51 | 13.16 | 1.49 |
| tNAA | 8.18 | 0.83 | 8.32 | 0.71 | 8.20 | 0.65 |
| tCr | 6.28 | 0.54 | 6.56**a | 0.64 | 6.34 | 0.53 |
| Cho | 1.80 | 0.19 | 1.91* | 0.19 | 1.82 | 0.20 |
| Ins | 4.80 | 0.50 | 5.12* | 0.55 | 4.86 | 0.58 |
| Subcomponents of Glx | ||||||
| Glu | 8.62 | 0.84 | 9.32****a | 1.01 | 8.80 | 1.08 |
| Gln | 4.41 | 0.87 | 4.59 | 0.85 | 4.42 | 0.95 |
CSF-corrected metabolite levels in institutional units (i.u.)
PBO placebo, AMP d-amphetamine, MA methamphetamine, Glx Glx complex, tNAA total N-acetyl-aspartate and N-acetylaspartyl-glutamic acid, tCr total creatine and phosphocreatine, Cho choline-containing compounds, Ins myo-inositol, Glu glutamate, Gln glutamine
*Significantly different from placebo at *p < .05, **p < .01, ***p < .005, ****p < .0001
aSurvives Bonferroni correction for multiple comparisons (adjusted alpha = .007). n = 24, 63–66 MRS spectra per outcome